Professionals 239 Users Online

Drug-Resistant Tuberculosis Treatment Market

Drug-Resistant Tuberculosis Treatment Market - Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031

Drug-Resistant Tuberculosis Treatment Market Segmented By Drug Class such as Amoxicillin/Clavulanate, Bedaquiline, Carbapenems with Clavulanic Acid, Clofazimine, Cycloserine, Delamanid, Ethambutol, Ethionamide and Prothionamide, Fluoroquinolones,Azithromycin, Clarithromycin, p-Aminosalicylic Acid Pyrazinamide used for Diseases like Multidrug-Resistant TB (MDR TB), Extensively Drug-resistant TB (XDR TB) with First-Line Anti-TB Drugs and Second-Line Anti-TB Drugs Treatment Type

Drug-Resistant Tuberculosis Treatment Market Forecast and CAGR

According to the latest research by Persistence Market Research, the Drug-Resistant Tuberculosis Treatment market is set to witness a growth of 5% during 2021-2031. Demand for Drug-Resistant Tuberculosis Treatment expects to witness steady recovery in the short-term, with an optimistic growth outlook in the long run. The growing advancement for the Drug-Resistant Tuberculosis Treatment market industry will offer lucrative opportunities in near future.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

What are the major drivers of the Drug-Resistant Tuberculosis Treatment Market?

The WHO has described the global effects of multidrug-resistant tuberculosis (MDR TB) as a “public health crisis”. In 2013, an estimated 480,000 new cases and 210,000 deaths were caused by MDR TB which is defined by resistance to isoniazid and rifampin, the 2 most effective anti-TB drugs.

In addition, approximately 9% of MDR TB cases are believed to be extensively drug-resistant (XDR TB), which implies additional resistance to any fluoroquinolone and at least 1 injectable second-line drug. Treatment of MDR and XDR TB requires prolonged therapy with toxic, poorly tolerated medications, and for patients in developing countries, access to active drugs may be limited.

Drug-resistant TB is the largest single source of antimicrobial resistance in the world. According to WHO, approximately half a million people worldwide are diagnosed with multi-drug-resistant TB each year, and about 8.5% of those people have XDR TB.

Common TB treatments don’t work on XDR TB, so people with this extreme form of the disease need to take a combination of around eight drugs for more than a year. This growing number of drug-resistant tuberculosis will act as a driver for drug-resistant tuberculosis treatment market growth in the forecasted period.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

The Increase in R&D in Therapy Is Anticipated To Enhance the Market Growth

There has been continuous research going on in the drug-resistant tuberculosis treatment field. FDA is actively involved in the approval of the related drugs. For instance, in Aug 2019, FDA Approves Pretomanid for Highly Drug-Resistant Forms of Tuberculosis. This continuous R&D will attract the market in the forecasted period.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

North America Drug-Resistant Tuberculosis Treatment Market Outlook

North America held the majority of the revenue share of the global market in 2020. There has been a significant increase in the number of cases of MDR-TB in the United States. Although cases of MDR-TB have been reported from many areas of the country, the majority of the cases are concentrated in large urban areas.

MDR-TB is difficult and expensive to treat. CDC has developed a National Action Plan to Combat Multidrug-Resistant Tuberculosis. The U.S. has large support from government and insurance providers to facilitate the healthcare system. As the cell therapy treatment are expensive the favorable healthcare system of the region will promote the growth of the market in the forecasted period. Besides being a developed nation clinical trials are going on in the region facilitating the adoption of cell therapy.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Asia Demand Outlook for Drug-Resistant Tuberculosis Treatment Market

Asia is the second-largest market for drug-resistant tuberculosis treatment. According to WHO, it is estimated that 171,000 Rifampicin-resistant (RR) and multi-drug-resistant TB (MDR-TB) cases accounting for more than 35% of global burden appeared in the region in 2019, of which around 70,000 were started on second-line treatment in the same year.

Six out of the 30 high TB (and MDR-TB) burden countries are in the region are Bangladesh, the Democratic People’s Republic of Korea, India, Indonesia, Myanmar, and Thailand. Central Asia accounts for 85% of the tuberculosis incidence and more than 90% of drug-resistant tuberculosis cases emerging in the region. This huge prevalence of MDR and XDR in the region will give rise to a drug-resistant tuberculosis treatment market in the forecasted period.

Who are the key players in the Drug-Resistant Tuberculosis Treatment Market?

Some of the key players of Drug-Resistant Tuberculosis Treatment include

  • Sanofi
  • Novartis AG
  • Endo International plc
  • CMP Pharma
  • STI Pharma LLC
  • Akorn Incorporated
  • Lupin
  • Johnson & Johnson Services Inc.
  • Macleods Pharmaceuticals Ltd
  • Pfizer Inc
  • Hikma Pharmaceuticals PLC
  • Lannett
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd
  • Fresenius Kabi AG
  • Others.

Companies offering Drug-Resistant Tuberculosis Treatment are involved in existing product upgrades, new product launches, mergers and acquisitions, and regional expansion to enhance their market position.

Key Segments

By Drug Class

  • Amoxicillin/Clavulanate
  • Bedaquiline
  • Carbapenems with Clavulanic Acid
  • Clofazimine
  • Cycloserine
  • Delamanid
  • Ethambutol
  • Ethionamide and Prothionamide
  • Fluoroquinolones
    • Levofloxacin
    • Moxifloxacin
    • Ciprofloxacin
    • Ofloxacin
  • Linezolid
  • Macrolides
    • Azithromycin
    • Clarithromycin
  • p-Aminosalicylic Acid
  • Pyrazinamide

By Disease Type

  • Multidrug-Resistant TB (MDR TB)
  • Extensively Drug-resistant TB (XDR TB)

By Treatment Type

  • First-Line Anti-TB Drugs
  • Second-Line Anti-TB Drugs
  • Others

By Distribution channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

By Region

  • North America
    • US
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Russia
    • Benelux
    • Rest of Latin America
  • East Asia
    • China
    • Japan
    • South Korea
  • South Asia
    • India
    • ASEAN
    • Rest of South Asia
  • Oceania
    • Australia
    • New Zealand
  • Middle East and Africa
    • GCC Countries
    • North Africa
    • South Africa
    • Turkey
    • Rest of Middle East

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Drug-Resistant Tuberculosis Treatment Market Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size recent industry trends
  • Key Competition landscape
  • Strategies for key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance
  • Must-have information for market players to sustain and enhance their market footprint

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.

- Companies Covered in This Report -

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate